Characterization of Psychotropic PRN Medications in a Canadian Psychiatric Intensive Care Unit

Abstract

BACKGROUND:

Pro re nata (PRN) antipsychotics and benzodiazepines are routinely used for the rapid stabilization of acutely agitated patients. Despite the popular use of PRN medications in mental health units, primary literature supporting efficacy and safety is poor, and there is no single universally accepted practice guideline. PRN psychotropic medications have the potential to cause adverse effects when used inappropriately.

AIMS:

Our objective was to characterize the prescribing, administration, and documentation practices of PRN psychotropic medications in a psychiatric intensive care unit.

METHODS:

We conducted a retrospective chart review of patients admitted to a 12-bed psychiatric intensive care unit between June and September 2018. All PRN antipsychotic and benzodiazepine orders, administrations, documentation practices, and attempted nonpharmacological strategies were assessed for each order and patient. Descriptive statistics were used to analyze data.

RESULTS:

Thirty-two patients with a total of 123 physicians’ orders and 1,179 PRN administrations of antipsychotics and benzodiazepines were reviewed. Of the total administrations, 720 (61%) were combinations with at least two psychotropic agents. Forty-one (33%) physicians’ orders had a prescribed indication, and 559 (47%) administrations had an attempted nonpharmacological method prior to PRN administration. Eight patients (25%) had antipsychotic PRN orders, which exceeded the total daily maximum dose. Three adverse drug effects were attributed to PRN administration.

CONCLUSIONS:

Areas of improvement that we identified included documentation practices of effectiveness of administered PRNs, prescriptions to include clear indications and dosage within the 24-hour maximum limits, and documentation of nonpharmacological methods utilized.

Keywords

psychotropic drugs antipsychotic agents benzodiazepines psychiatry intensive care unit

Get full access to this article

View all access options for this article.

References

Allen

M. H.

Currier

G. W.

Carpenter

Ross

R. W.

Docherty

J. P

., & Expert Consensus Panel for Behavioral Emergencies 2005. (2005). The expert consensus guideline series: Treatment of behavioral emergencies 2005. Journal of Psychiatric Practice, 11(1), 5-108. https://doi.org/10.1097/00131746-200511001-00002

Baker

J. A.

Lovell

Harris

(2008a). A best-evidence synthesis review of the administration of psychotropic pro re nata (PRN) medication in in-patient mental health settings. Journal of Clinical Nursing, 17(9), 1122-1131. https://doi.org/10.1111/j.1365-2702.2007.02236.x

Baker

J. A.

Lovell

Harris

(2008b). The impact of a good practice manual on professional practice associated with psychotropic PRN in acute mental health wards: An exploratory study. International Journal of Nursing Studies, 45(10), 1403-1410. https://doi.org/10.1016/j.ijnurstu.2008.01.004

Baker

J. A.

Lovell

Harris

Campbell

(2007). Multidisciplinary consensus of best practice for pro re nata (PRN) psychotropic medications within acute mental health settings: A Delphi study. Journal of Psychiatric and Mental Health Nursing, 14(5), 478-484. https://doi.org/10.1111/j.1365-2850.2007.01112.x

Bowers

James

Quirk

Simpson

Stewart

Hodsoll

(2015). Reducing conflict and containment rates on acute psychiatric wards: The Safewards cluster randomised controlled trial. International Journal of Nursing Studies, 52(9), 1412-1422. https://doi.org/10.1016/j.ijnurstu.2015.05.001

Cleary

Horsfall

Jackson

O’Hara-Aarons

Hunt

G. E.

(2012). Patients’ views and experiences of pro re nata medication in acute mental health settings. International Journal of Mental Health Nursing, 21(6), 533-539. https://doi.org/10.1111/j.1447-0349.2012.00814.x

Cullen

A. E.

Bowers

Khondoker

Pettit

Achilla

Koeser

Moylan

Baker

Quirk

Sethi

Stewart

McCrone

Tulloch

A. D.

(2018). Factors associated with use of psychiatric intensive care and seclusion in adult inpatient mental health services. Epidemiology and Psychiatric Sciences, 27(1), 51-61. https://doi.org/10.1017/S2045796016000731

Douglas-Hall

Whicher

E. V.

(2015). “As required” medication regimens for seriously mentally ill people in hospital. The Cochrane Database of Systematic Reviews, (2), CD003441. https://doi.org/10.1002/14651858.CD003441.pub3

Friedman

Nurenberg

J. R.

Birnbaum

Schleifer

S. J.

(2012). Using structured clinical feedback to encourage alternatives to use of “P.R.N.” medication in a state psychiatric hospital. Journal of Psychiatric Practice, 18(5), 381–387. https://doi.org/10.1097/01.pra.0000419823.69914.c7

10.

Garriga

Pacchiarotti

Kasper

Zeller

S. L.

Allen

M. H.

Vázquez

Baldaçara

San

McAllistor-Williams

R. H.

Fountoulakis

K. N.

Courtet

Naber

Chan

E. W.

Fagiolini

Möller

H. J.

Grinze

Llorca

P. M.

Jafe

R. L.

Yatham

L. N.

. . . Vieta

. (2016). Assessment and management of agitation in psychiatry: Expert consensus. World Journal of Biological Psychiatry, 17(2), 86-128. https://doi.org/10.3109/15622975.2015.1132007

11.

Geffen

Cameron

Sorensen

Stokes

Roberts

M. S.

Geffen

(2002). Pro re nata medication for psychoses: The knowledge and beliefs of doctors and nurses. Australian & New Zealand Journal of Psychiatry, 36(5), 642-648. https://doi.org/10.1046/j.1440-1614.2002.01068.x

12.

Haw

Wolstencroft

(2014). A study of the prescription and administration of sedative PRN medication to older adults at a secure hospital. International Psychogeriatrics, 26(6), 943-951. https://doi.org/10.1017/S1041610214000179

13.

Hayes

Russ

M. J.

(2016). Discontinuing the Use of PRN intramuscular medication for agitation in an acute psychiatric hospital. Psychiatric Quarterly, 87(1), 25-29. https://doi.org/10.1007/s11126-015-9359-1

14.

Hilton

M. F.

Whiteford

H. A.

(2008). Pro re nata medication for psychiatric inpatients: Time to act. Australian & New Zealand Journal of Psychiatry, 42(7), 555-564. https://doi.org/10.1080/00048670802119804

15.

Institute of Psychiatry Health Service and Population Research. (2020). Safewards. http://www.safewards.net/

16.

Joukamaa

Heliövaara

Knekt

Aromaa

Raitasalo

Lehtinen

(2006). Schizophrenia, neuroleptic medication and mortality. British Journal of Psychiatry, 188(2), 122-127. https://doi.org/10.1192/bjp.188.2.122

17.

Jovaisas

(Ed.). (2015). Compendium of pharmaceuticals and specialties. Canadian Pharmacists Association.

18.

Lehman

A. F.

Lieberman

J. A.

Dixon

L. B.

McGlashan

T. H.

Miller

A. L.

Perkins

D. O.

Kreyenbuhl

., & Steering Committee on Practice Guidelines. (2004). Practice guideline for the treatment of patients with schizophrenia, second edition. American Journal of Psychiatry, 161(2), 1-56.

19.

A.-S.

(2014). Administered antipsychotic pro re nata medications in psychiatric inpatients: Pre- and post-accreditation comparison. Saudi Medical Journal, 35(2), 172-177.

20.

Martin

Arora

Fischler

Tremblay

(2017). Descriptive analysis of pro re nata medication use at a Canadian psychiatric hospital. International Journal of Mental Health Nursing, 26(4), 402-408. https://doi.org/10.1111/inm.12265

21.

Mullen

Drinkwater

(2011). Pro re nata use in a psychiatric intensive care unit. International Journal of Mental Health Nursing, 20(6), 409-417. https://doi.org/10.1111/j.1447-0349.2011.00746.x

22.

Naranjo

C. A.

Busto

Sellers

E. M.

Sandor

Ruiz

Roberts

E. A.

Janecek

Domecq

Greenblatt

D. J.

(1981). A method for estimating the probability of adverse drug reactions. Clinical Pharmacology & Therapeutics, 30(2), 239-245. https://doi.org/10.1038/clpt.1981.154

23.

National Collaborating Centre for Mental Health. (2015). Violence and aggression: Short-term management in mental health, health and community settings: Updated edition. British Psychological Society. http://www.ncbi.nlm.nih.gov/books/NBK305020/

24.

National Collaborating Centre for Nursing and Supportive Care. (2005). Violence: The short-term management of disturbed/violent behaviour in in-patient psychiatric settings and emergency departments. Royal College of Nursing. http://www.ncbi.nlm.nih.gov/books/NBK55521/

25.

Patel

M. X.

Sethi

F. N.

Barnes

T. R.

Dix

Dratcu

Fox

Garriga

Haste

J. C.

Kahl

K. G.

Lingford-Hughes

McAllister-Williams

O’Brien

Parker

Paterson

Paton

Posporelis

Taylor

D. M.

Vieta

Völlm

. . . Woods

(2018). Joint BAP NAPICU evidence-based consensus guidelines for the clinical management of acute disturbance: De-escalation and rapid tranquillisation. Journal of Psychopharmacology (Oxford, England), 32(6), 601-640. https://doi.org/10.1177/0269881118776738

26.

Raja

Azzoni

Lubich

(1997). Aggressive and violent behavior in a population of psychiatric inpatients. Social Psychiatry & Psychiatric Epidemiology, 32(7), 428-434. https://doi.org/10.1007/BF00788184

27.

Rampling

Furtado

Winsper

Marwaha

Lucca

Livanou

Singh

S. P.

(2016). Non-pharmacological interventions for reducing aggression and violence in serious mental illness: A systematic review and narrative synthesis. European Psychiatry, 34, 17-28. https://doi.org/10.1016/j.eurpsy.2016.01.2422

28.

Rossi

Swan

M. C.

Isaacs

E. D.

(2010). The violent or agitated patient. Emergency Medicine Clinics of North America, 28(1), 235-256. https://doi.org/10.1016/j.emc.2009.10.006

29.

Royal College of Psychiatrists. (2014). Consensus statement on high-dose antipsychotic medication. https://www.rcpsych.ac.uk/docs/default-source/improving-care/better-mh-policy/college-reports/college-report-cr190.pdf?sfvrsn=54f5d9a2_2

30.

Stewart

Robson

Chaplin

Quirk

Bowers

(2012). Behavioural antecedents to pro re nata psychotropic medication administration on acute psychiatric wards. International Journal of Mental Health Nursing, 21(6), 540-549. https://doi.org/10.1111/j.1447-0349.2012.00834.x

31.

Use of Antipsychotics and/or Benzodiazepines as Rapid Tranquilization in In-Patients of Mental Facilities and Emergency Departments: A Review of the Clinical Effectiveness and Guidelines. (2015). Canadian Agency for Drugs and Technologies in Health. http://www.ncbi.nlm.nih.gov/books/NBK350030/

32.

Usher

Lindsay

Sellen

(2001). Mental health nurses’ PRN psychotropic medication administration practices. Journal of Psychiatric and Mental Health Nursing, 8(5), 383-390. https://doi.org/10.1046/j.1365-2850.2001.00407.x

33.

van Os

Kapur

(2009). Schizophrenia. Lancet (London, England), 374(9690), 635-645. https://doi.org/10.1016/S0140-6736(09)60995-8

34.

Walker

(1991). PRN psychotropic drug use on a psychiatric unit. Psychiatric Quarterly, 62(1), 1-8. https://doi.org/10.1007/BF01958834

35.

Yatham

L. N.

Kennedy

S. H.

Parikh

S. V.

Schaffer

Bond

D. J.

Frey

B. N.

Sharma

Goldstein

B. I.

Rej

Beaulieu

Alda

MacQueen

Milev

R. V.

Ravindran

O’Donovan

McIntosh

Lam

R. W.

Vazquez

Kapczinski

. . . Berk

(2018). Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disorders, 20(2), 97-170. https://doi.org/10.1111/bdi.12609

36.

Zareifopoulos

Panayiotakopoulos

(2019). Treatment options for acute agitation in psychiatric patients: Theoretical and empirical evidence. Cureus, 11(11), e6152. https://doi.org/10.7759/cureus.6152